JBiSE  Vol.6 No.2 A , February 2013
Ezetimibe Completely Replaced LDL-Apheresis for the Treatment of Familial Hypercholesterolemia and Coronary Artery Disease after CABG—A Case Report
Abstract: Intensive treatment of hyperlipidemia is an important factor in the prevention of cardiovascular disease. Among several therapies, statins are well recognized as playing a central role, although low density lipoprotein bound cholesterol-apheresis can be used to treat very severe cases of familial hypercholesterolemia. However, statins are not always effective on their own and, recently, ezetimibe has emerged as a unique anti- hypercholesterolemic drug that acts as a cholesterol transporter inhibitor; its role is only partially understood. I experienced rare case that appeared to benefit from ezetimibe therapy, and report them as they help increase our knowledge of this novel drug.
Cite this paper: Yokoyama, I. (2013) Ezetimibe Completely Replaced LDL-Apheresis for the Treatment of Familial Hypercholesterolemia and Coronary Artery Disease after CABG—A Case Report. Journal of Biomedical Science and Engineering, 6, 232-235. doi: 10.4236/jbise.2013.62A028.

[1]   De Lorgeril, M., Renaud, S., Mamelle, N., et al. (1994) Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet, 343, 1454 1459. doi:10.1016/S0140-6736(94)92580-1

[2]   Scandinavian Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet, 344, 1383-1389.

[3]   Shepherd, J., Cobbe, S.M., Ford, I., et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, 333, 1301-1307. doi:10.1056/NEJM199511163332001

[4]   The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357. doi:10.1056/NEJM199811053391902

[5]   Lewis, S.J., Sacks, F.M., Mitchell, J.S., et al. (1998) Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. Journal of the American College of Cardiology, 32, 140-146. doi:10.1016/S0735-1097(98)00202-2

[6]   Gould, K.L., Ornish, D., Kirkeeide, R., et al. (1992) Improved stenosis geometry by quantitative coronary arte riography after vigorous risk factor modification. American Journal of Cardiology, 69, 845-853. doi:10.1016/0002-9149(92)90781-S

[7]   Pitt, B., Waters, D., Brown, W.V., et al. (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus revas cularization treatment investigators. New England Journal of Medicine, 341, 70-76. doi:10.1056/NEJM199907083410202

[8]   Ge, L., Wang, J., Qi, W., et al. (2008) The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol induced internalization of NPC1L1. Cell Metabolism, 7, 508-519. doi:10.1016/j.cmet.2008.04.001

[9]   Stein, E., Stender, S., Mata, P., et al. (2004) Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co administered with atorvastatin. American Heart Journal, 148, 447-455. doi:10.1016/j.ahj.2004.03.052

[10]   Gordon, B.R., Kelsey, S.F., Dau, P.C., et al. (1998) Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. American Journal of Cardiology, 81, 407-411. doi:10.1016/S0002-9149(97)00947-8

[11]   Thompson, G.R., Barbir, M., Davies, D., et al. (2010) Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis, 208, 317-321. doi:10.1016/j.atherosclerosis.2009.06.010

[12]   Lally, S., Tan, C.Y., Owens, D. and Tomkin, G.H. (2006) Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: The role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia, 49, 1008-1016. doi:10.1007/s00125-006-0177-8